Switch to:
More From Other Websites
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 13 2017
Why Navidea can recover no more than $12M if it wins against ex-lender in court Mar 13 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 09 2017
Navidea closes Lymphoseek sale to Cardinal Health; lender CRG accepts loan payment, drops liens Mar 06 2017
Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health Mar 03 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Mar 02 2017
Cardinal Health helps Navidea settle lender's payoff – for now Feb 24 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Feb 23 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Feb 16 2017
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 10 2017
Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events Jan 27 2017
Navidea to Present at Upcoming Investor Conference Jan 06 2017
Navidea to Present at Upcoming Investor Conference Jan 06 2017
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : December 29, 2016 Dec 29 2016
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : December 13, 2016 Dec 13 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 30 2016
Edited Transcript of NAVB earnings conference call or presentation 3-Nov-16 12:30pm GMT Nov 28 2016
ETFs with exposure to Navidea Biopharmaceuticals, Inc. : November 28, 2016 Nov 28 2016
Navidea Signs Asset Purchase Agreement with Cardinal Health Nov 23 2016
Navidea Signs Asset Purchase Agreement with Cardinal Health Nov 23 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Financials Nov 17 2016
Navidea Biopharmace21860helestones Nov 14 2016
NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
ETF’s with exposure to Navidea Biopharmaceuticals, Inc. : November 8, 2016 Nov 08 2016
Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7,... Nov 07 2016
Navidea Reports 2016 Third Quarter Financial Results Nov 03 2016
Navidea Biopharmaceuticals to Announce Third Quarter 2016 Financial Results on November 3, 2016 Oct 27 2016
Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer Sep 26 2016
Navidea Achieves $1 Million in Lymphoseek® Commercial Milestones Sep 22 2016
Navidea’s Lymphoseek® Receives Positive Opinion in Europe for a New Reduced Mass Vial Sep 16 2016
Navidea to Present at Upcoming Investor Conferences Sep 14 2016
Navidea Biopharmaceuticals to Hold Investor Update Call Sep 06 2016
Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of... Sep 06 2016
Navidea Biopharmaceuticals Announces 2016 Annual Meeting Results Aug 11 2016
Navidea Executes a Term Sheet with Cerveau Technologies to Sublicense NAV4694 Aug 08 2016
Navidea Reports Second Quarter 2016 Financial Results Aug 04 2016
Navidea Biopharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016 Jul 28 2016
Navidea Announces Presentation of Results Demonstrating Performance of Lymphoseek® in Breast Cancer... Jun 16 2016
Navidea to Provide Shareholder Update Jun 14 2016
Navidea Announces Data Presentations at 2016 Annual Meeting of the Society of Nuclear Medicine and... Jun 02 2016
$1.8 Million Fast-Track NIH SBIR Grant for Manocept™ Immunotherapeutics Evaluation in Kaposi’s... May 26 2016
Navidea Provides Financing Update May 23 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK